June 13, 2026 08:29 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Mamata's nightmare deepens! Saayoni Ghosh, Dev, Rachana Banerjee among 19 rebel MPs seeking TMC split | Trump claims US 'ended war with Iran', Tehran yet to confirm a deal | Heartbreak for Indian sports: Manu Bhaker's mentor Jaspal Rana passes away at 49 | Three Indian seafarers, missing after US strike on tanker near Oman, confirmed dead | 'Choose your side': TMC MP Kalyan Banerjee's ultimatum to Mamata in open revolt against Abhishek | Fresh trouble for Abhishek Banerjee! Calcutta HC orders TMC MP to appear before CID in forgery case by 6 pm today | 'No resignation, no retreat': Cockroach Janta Party takes paper leak protest nationwide | TCS goes all-in on AI! Partners with Anthropic, gives Claude access to 50,000 employees | Viral video outrage! Ola driver brutally assaults 70-year-old man over spitting row; arrested after Shinde's personal intervention | Mamata under pressure! Third Rajya Sabha MP Prakash Chik Baraik quits, hints at BJP move
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm